Summary:
A phase 2/3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults with ADHD to assess to efficacy and safety.
Qualified Participants Must:
• Be 18 - 55 years old
•
Have a diagnosis of ADHD
•
Additional eligibility criteria apply
Qualified Participants May Receive:
Up to $750 for time and tavel-related expenses